The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease

Overview

Journal J Pers Med

Date 2022 Oct 27

PMID 36294700

Authors

Hilda T Maibach

Michael J Brownstein

Steven M Hersch

Karen E Anderson

Debra E Itzkowitz

Eve M Damiano

Neal G Simon

Affiliations

Soon will be listed here.

Abstract

SRX246, an orally available CNS penetrant vasopressin (VP) V1a receptor antagonist, was studied in Huntington's disease (HD) patients with irritability and aggressive behavior in the exploratory phase 2 trial, Safety, Tolerability, and Activity of SRX246 in Irritable HD patients (STAIR). This was a dose-escalation study; subjects received final doses of 120 mg BID, 160 mg BID, or placebo. The compound was safe and well tolerated. In this paper, we summarize the results of exploratory analyses of measures of problematic behaviors, including the Cohen-Mansfield Agitation Inventory (CMAI), Aberrant Behavior Checklist (ABC), Problem Behaviors Assessment-short form (PBA-s), Irritability Scale (IS), Clinical Global Impression (CGI), HD Quality of Life (QoL), and Caregiver Burden questionnaires. In addition to these, we asked subjects and caregivers to record answers to short questions about mood, irritability, and aggressive conduct in an eDiary. STAIR was the first rigorously designed study of behavioral endpoints like these in HD. The exploratory analyses showed that SRX246 reduced aggressive acts. Readily observed behaviors should be used as trial endpoints.

Citing Articles

Discovery and evaluation of a novel F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity.

Hu J, Li Y, Dong C, Wei H, Liao K, Wei J Acta Pharm Sin B. 2024; 14(9):4014-4027.

PMID: 39309503 PMC: 11413668. DOI: 10.1016/j.apsb.2024.05.033.

Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention.

Hu H, Zarate Jr C, Verbalis J Psychiatry Clin Neurosci. 2024; 78(9):495-506.

PMID: 38923665 PMC: 11371531. DOI: 10.1111/pcn.13703.

References

Zink C, Kempf L, Hakimi S, Rainey C, Stein J, Meyer-Lindenberg A . Vasopressin modulates social recognition-related activity in the left temporoparietal junction in humans. Transl Psychiatry. 2012; 1:e3. PMC: 3309468. DOI: 10.1038/tp.2011.2. View

Zink C, Stein J, Kempf L, Hakimi S, Meyer-Lindenberg A . Vasopressin modulates medial prefrontal cortex-amygdala circuitry during emotion processing in humans. J Neurosci. 2010; 30(20):7017-22. PMC: 2880169. DOI: 10.1523/JNEUROSCI.4899-09.2010. View

Aman M, Singh N, Stewart A, Field C . The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985; 89(5):485-91. View

Rabinowitz J, Davidson M, De Deyn P, Katz I, Brodaty H, Cohen-Mansfield J . Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005; 13(11):991-8. DOI: 10.1176/appi.ajgp.13.11.991. View

Brownstein M, Simon N, Long J, Yankey J, Maibach H, Cudkowicz M . Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020; 9(11). PMC: 7696926. DOI: 10.3390/jcm9113682. View

Bouwens J, van Duijn E, van der Mast R, Roos R, Giltay E . Irritability in a Prospective Cohort of Huntington's Disease Mutation Carriers. J Neuropsychiatry Clin Neurosci. 2015; 27(3):206-12. DOI: 10.1176/appi.neuropsych.14030051. View

Yu R, Topiwala A, Jacoby R, Fazel S . Aggressive Behaviors in Alzheimer Disease and Mild Cognitive Impairment: Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry. 2018; 27(3):290-300. PMC: 6399100. DOI: 10.1016/j.jagp.2018.10.008. View

Guillon C, Koppel G, Brownstein M, Chaney M, Ferris C, Lu S . Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem. 2007; 15(5):2054-80. PMC: 2067992. DOI: 10.1016/j.bmc.2006.12.031. View

Thompson R, Gupta S, Miller K, Mills S, Orr S . The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology. 2003; 29(1):35-48. DOI: 10.1016/s0306-4530(02)00133-6. View

10.

Cohen-Mansfield J . Agitation in the elderly. Adv Psychosom Med. 1989; 19:101-13. DOI: 10.1159/000417403. View

11.

Ghosh R, Tabrizi S . Clinical Features of Huntington's Disease. Adv Exp Med Biol. 2018; 1049:1-28. DOI: 10.1007/978-3-319-71779-1_1. View

12.

van Duijn E . Treatment of Irritability in Huntington's Disease. Curr Treat Options Neurol. 2010; 12(5):424-33. PMC: 2918785. DOI: 10.1007/s11940-010-0088-3. View

13.

Cohen-Mansfield J . Assessment of agitation. Int Psychogeriatr. 1996; 8(2):233-45. DOI: 10.1017/s104161029600261x. View

14.

Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B . Structural brain correlates of irritability and aggression in early manifest Huntington's disease. Brain Imaging Behav. 2020; 15(1):107-113. DOI: 10.1007/s11682-019-00237-x. View

15.

Insel T . The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010; 65(6):768-79. PMC: 2847497. DOI: 10.1016/j.neuron.2010.03.005. View

16.

Weiner M, Williams B, Risser R . Assessment of behavioral symptoms in community-dwelling dementia patients. Am J Geriatr Psychiatry. 1997; 5(1):26-30. View

17.

Tractenberg R, Gamst A, Weiner M, Koss E, Thomas R, Teri L . Frequency of behavioral symptoms characterizes agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2001; 16(9):886-91. PMC: 4373072. DOI: 10.1002/gps.441. View

18.

Kraemer H, Wilson G, Fairburn C, Agras W . Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002; 59(10):877-83. DOI: 10.1001/archpsyc.59.10.877. View

19.

Young L, Toloczko D, Insel T . Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain. J Neuroendocrinol. 1999; 11(4):291-7. DOI: 10.1046/j.1365-2826.1999.00332.x. View

20.

Chatterjee A, Anderson K, Moskowitz C, Hauser W, Marder K . A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2005; 17(3):378-83. DOI: 10.1176/jnp.17.3.378. View